Effective therapeutics to counteract the formation of amyloid plaques in Alzheimer’s disease and type 2 diabetes are not yet available. Scientists have now come a little bit closer to a solution: They have described a new class of designed macrocyclic peptides that are highly potent inhibitors of amyloid formation.